However, TTs lack durable responses and it was recently demonstrated that first-line nivolumab–ipilimumab followed by BRAF/MEK-inhibition on progression had the most favorable OS in metastatic melanoma [28]. This evidence concerns the gene BRAF and metastatic melanoma.